PHAGEPHARM Completes Series B Financing, with CEC Capital as Exclusive Financial Advisor

Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders.

CEC Capital served as exclusive financial advisor for this transaction.

As a pioneer in the domestic animal health sector, the company has established the largest enterprise-level phage library in China and developed a variety of phage solutions targeting bacterial diseases in livestock, aquaculture, and pet health.

The funds raised from this financing will be primarily used for the construction of a GMP-certified phage production facility and for clinical trials of new phage drugs. The company has already submitted clinical trial applications for a class of new veterinary drugs based on phage therapy to the Ministry of Agriculture and Rural Affairs. Multiple new phage drugs are in development, with registration applications maintaining an industry-leading position. The company is committed to continuously building the leading domestic phage-based biotherapy solutions.